title: Anemia and risk of hospitalization in pediatric chronic kidney disease.
abstract: OBJECTIVE
  Anemia is a well known complication of chronic kidney disease (CKD); however, the prevalence of anemia within CKD stages in the pediatric population has not been established. Additionally, the associated morbidity of anemia in the pediatric CKD population has not been elucidated.
  
  
  METHODS
  2,779 patients ages 2 yr and older in the North American Pediatric Renal Trials and Collaborative Studies database with CKD stage II to V (excluding dialysis or previous transplant patients) were identified. Descriptive statistics and multivariate modeling using logistic regression was performed to determine the prevalence of anemia and to evaluate the correlation between baseline anemia and hospitalization.
  
  
  RESULTS
  The prevalence of anemia (hematocrit < 33%) increased from 18.5% in CKD stage II to 68% in CKD stage V (predialysis). Anemic children were 55% more likely to be hospitalized when compared with nonanemic children (odds ratio 1.55; 95% confidence interval 1.23 to 1.94). Similar results were obtained using hematocrit cutoffs of 36 and 39%.
  
  
  CONCLUSIONS
  In this pediatric predialysis CKD population, anemia increases with increasing CKD stage and is significantly associated with hospitalization risk. Hematocrit levels above 36 and 39% were not associated with increased risk of hospitalization. Further examination into the effect of correcting anemia on hospitalization rates may provide additional useful information.
authors.affiliation: Division of Pediatric Nephrology, University of New Mexico, Albuquerque, NM 87131, USA. astaples@salud.unm.edu
authors.forename: Amy O
authors.initials: AO
authors.lastname: Staples
authors.forename: Craig S
authors.initials: CS
authors.lastname: Wong
authors.forename: Jodi M
authors.initials: JM
authors.lastname: Smith
authors.forename: Debbie S
authors.initials: DS
authors.lastname: Gipson
authors.forename: Guido
authors.initials: G
authors.lastname: Filler
authors.forename: Bradley A
authors.initials: BA
authors.lastname: Warady
authors.forename: Karen
authors.initials: K
authors.lastname: Martz
authors.forename: Larry A
authors.initials: LA
authors.lastname: Greenbaum
mesh_terms: D000293:Adolescent; D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D002170:Canada / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006397:Hematinics / Q000627:therapeutic use; D006400:Hematocrit; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D016017:Odds Ratio; D015995:Prevalence; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D006397:Hematinics; D004921:Erythropoietin